Long-term morbidity of IgA nephropathy in children evaluated with newly proposed remission criteria in Japan

Shoko Matsushita(Tokyo Metropolitan Children's Medical Center), Masataka Honda(Rikkyo University), Tomoyuki Sakai(Tokyo Metropolitan Children's Medical Center), Shojiro Okamoto(Tokai University Hachioji Hospital), Yoshinobu Nagaoka(Seoul National University Children's Hospital), Yusuke Okuda(Kitasato University), Hiroshi Hataya(Japanese Society for Dialysis Therapy), Kenji Ishikura(Kitasato University), Takashi Ando(Japan Clinical Cancer Research Organization), Kentaro Ogata(National Defense Medical College), Riku Hamada, Ryoko Harada(Tokyo Metropolitan Children's Medical Center), Yuko Hamasaki(Toho University)
Clinical and Experimental Nephrology
March 23, 2015
10.1007/s10157-015-1105-3
Cited by 14

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|278
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease
|Clinical and Experimental Nephrology|2013|267
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
|Pediatric Nephrology|2021|149
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
|Kidney International|2014|135